You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
Keep Reading →
July 3 - News
Companies know that to attract regular income-seeking investors, it helps to pay out high dividends.
Keep Reading →
July 1 - News
Famed investor Warren Buffett once called the high cost of health care a "tapeworm eating at our economic body." While he might be disgusted by the costs, it hasn't stopped ...
Keep Reading →
June 27 - Hedge Fund Analysis
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
June 27 - News
Let me preface this by saying that investing in the biotech sector can sometimes be nothing more than speculating.
Keep Reading →
June 27 - News
These two ratios provide an indication of how successful a company is at generating profits using shareholders' funds and debt, and they have a strong influence on dividend payments...
Keep Reading →
June 27 - News
Viagra changed the way below-the-belt jokes were told, and certainly, it empowered a lot of men in ways they couldn't have imagined. Without a doubt, Pfizer Inc.
Keep Reading →
June 25 - News
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Keep Reading →
June 24 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s long-run total return for shareholders (capital appreciation and dividends over the past 10 years) has lagged behind that of the average...
Keep Reading →
June 24 - News
LONDON -- I'm always searching for shares that can help ordinary investors like you make money from the stock market.
Keep Reading →
June 24 - News
High dividend pharmaceutical stocks have been extremely popular in recent years.
Keep Reading →
June 21 - News
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors.
Keep Reading →
June 20 - News
Indeed, the shares currently yield an impressive 4.4% despite rising by more than 30% in the last three years alone.
Keep Reading →
June 20 - News
Botox may be best known for its ability to combat crow's feet and other facial wrinkles, but it also serves an important role in the medical community.
Keep Reading →
June 19 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer. Its one potential challenger...
Keep Reading →
June 18 - News
London-based pharmaceutical giant AstraZeneca plc (ADR) (NYSE:AZN) recently announced that it had agreed to purchase U.S.-based lung-drug manufacturer Pearl Therapeutics for at...
Keep Reading →
June 18 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Keep Reading →
June 18 - News
It may surprise you, but restless legs syndrome (RLS) affects 7% to 10% of the U.S. population, with varying degrees of severity.
Keep Reading →
June 18 - News
Recently, AstraZeneca plc (ADR) (NYSE:AZN) announced that it has agreed to acquire Pearl Therapeutics, the respiratory drug manufacturer, in a transaction worth around $1.15 billion...
Keep Reading →
June 17 - News
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Keep Reading →
June 13 - News
Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic.
Keep Reading →
June 12 - News
This money coming in is cash flow, and looking at a company's cash flow gives us -- as current or potential shareholders -- a sense of how well that company is doing at selling...
Keep Reading →
June 12 - News
AstraZeneca plc (ADR) (NYSE:AZN) announced the acquisition of Omthera Pharmaceuticals Inc (NASDAQ:OMTH), a company that went public just last month (April 11).
Keep Reading →
June 10 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s diabetes drug Avandia causes heart issues. Or maybe it doesn't.
Keep Reading →
June 10 - News
Is AstraZeneca plc (ADR) (NYSE:AZN) a healthy stock for your portfolio? Investors who are in the know are getting more bullish.
Keep Reading →
June 10 - News
Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS, Inc. (NASDAQ:VVUS) .
Keep Reading →
June 6 - Hedge Funds
When we think of big pharma companies, the company we think about constantly is Pfizer Inc.
Keep Reading →
June 6 - News
LONDON -- A popular way to dig out reasonably priced stocks with robust growth potential is through the "Growth at a Reasonable Price," or GARP, strategy.
Keep Reading →
June 5 - News
Editor's Note: The initial article refers to Abraxane's prostate cancer trials. That is incorrect, Abraxane has priority review for pancreatic cancer.
Keep Reading →
June 4 - News
The biotechnology sector is rapidly evolving, and what was a near-guarantee of success of getting a drug approved by the Food and Drug Administration 10 years ago is no longer...
Keep Reading →
June 3 - News
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
June 3 - News
The Food and Drug Administration stays busy with approvals, recommendations, and reviews.
Keep Reading →
June 3 - News
For a long time, Africa’s traditional enemy with regard to diseases have been communicable diseases like HIV and Malaria. Now, however, this trend is changing.
Keep Reading →
June 3 - News
If you'd ask most stock holders, hedge funds are assumed to be underperforming, outdated financial vehicles of yesteryear.
Keep Reading →
June 3 - News
According to most market participants, hedge funds are assumed to be underperforming, old financial vehicles of yesteryear.
Keep Reading →
June 3 - News
We'd all like to invest like the legendary Warren Buffett, turning thousands into millions or more.
Keep Reading →
May 31 - News
The field of synthetic biology is still in its infancy, with many of the most promising companies residing outside of public markets, but make no mistake: The bioeconomy is on...
Keep Reading →
May 31 - News
LONDON -- The economic crisis has forced governments worldwide to consider how they can deliver services more efficiently. Frequently, they are turning to the private sector.
Keep Reading →
May 30 - News
LONDON -- If you can keep your head while everyone around is losing theirs, you probably hold shares in GlaxoSmithKline plc (LON:GSK).
Keep Reading →
May 30 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) was in 18 hedge funds' portfolio at the end of March. GSK investors should be aware of a decrease in enthusiasm from smart money lately.
Keep Reading →
May 29 - News
General Electric Company (NYSE:GE) steadily pays out dividends to its shareholders. The payout amount has been increasing year over year for three years in a row.
Keep Reading →
May 29 - News
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc.
Keep Reading →
May 28 - News
Large, multinational companies have an unprecedented number of things pulling and pushing on their share price.
Keep Reading →
May 28 - News
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
May 28 - News
Bristol Myers Squibb Co. (NYSE:BMY) was in 33 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
May 24 - News
To most investors, hedge funds are seen as slow, outdated financial vehicles of the past.
Keep Reading →
May 24 - News
The Eurozone debt problems have held as a central focus of the financial markets since 2010.
Keep Reading →
May 24 - News
Any investor looking for the highest-paying dividend stocks would do well to start in Big Pharma, where many of the top picks offer yields in excess of 3% or 4%.
Keep Reading →
May 22 - News
LONDON -- It's been a long tough slog for GlaxoSmithKline plc (LON:GSK) shares, but things are looking up.
Keep Reading →
May 22 - News
